NCT04837638

Brief Summary

The overarching objective is to evaluate the relationship between diet and coronary artery calcification in patients with heterozygous familial hypercholesterolemia (HeFH). We will recruit adults with HeFH. They will have to complete questionnaires on diet, medication and lifestyle. Coronary artery calcification will be measured in each patient using a CT scan. Physiological and biochemical data will be collected.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
258

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 6, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 8, 2021

Completed
3 months until next milestone

Study Start

First participant enrolled

July 1, 2021

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

March 13, 2024

Status Verified

March 1, 2024

Enrollment Period

2.5 years

First QC Date

April 6, 2021

Last Update Submit

March 11, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Relationship between diet quality and coronary artery calcification (CAC)

    Diet quality indices reflecting different dimensions of diet will be used as the main exposure, including the Alternative Mediterranean Diet Index (AMED, 9-45 points), the Alternative Healthy Eating Index (AHEI, 0-100 points), the Dietary Approach to Stop Hypertension index (DASHi, 8-40 points), the healthy plant-based diet index (hPDI, 18-90 points) and the unhealthy plant-based diet index (uPDI, 18-90 points). Higher scores reflect higher diet quality, except for the uPDI which reflect lower diet quality. CAC will be measured using non-constrat CT scan. CAC scores will be quantified with the Agatston scoring method. Higher CAC scores reflect higher CAC.

    Diet questionnaire completion and CAC measurement will be completed with a 3 weeks period.

Secondary Outcomes (8)

  • Relationship between diet quality and LDL-cholesterol.

    Diet questionnaire completion and CVD risk factor measurement will be completed with a 3 weeks period.

  • Relationship between diet quality and Lipoprotein (a).

    Diet questionnaire completion and CVD risk factor measurement will be completed with a 3 weeks period.

  • Relationship between diet quality and intuitive eating.

    Diet questionnaire completion and psychological aspects of eating measurement will be completed with a 3 weeks period.

  • Relationship between diet quality and physical activity

    Diet questionnaire completion and lifestyle habit measurement will be completed with a 3 weeks period.

  • Relationship between diet quality and sleep.

    Diet questionnaire completion and lifestyle habit measurement will be completed with a 3 weeks period.

  • +3 more secondary outcomes

Study Arms (1)

Adults with HeFH

Adult men and women aged 18 to 65 years with genetically-defined HeFH.

Behavioral: Diet

Interventions

DietBEHAVIORAL

No intervention. Cross-section assessment of the relationship between diet, medication, lifestyle and coronary artery calcification.

Adults with HeFH

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult men and women with genetically-defined HeFH

You may qualify if:

  • \- Genetically-defined heterozygous familial hypercholesterolemia

You may not qualify if:

  • Homozygous FH
  • Personal history of cardiovascular disease
  • Personal history of cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute of nutrition and functional foods, Laval University

Québec, G1V0A6, Canada

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum and plasma.

MeSH Terms

Conditions

Hyperlipoproteinemia Type IICalcinosisFeeding Behavior

Interventions

Diet

Condition Hierarchy (Ancestors)

Lipid Metabolism, Inborn ErrorsMetabolism, Inborn ErrorsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesHyperlipoproteinemiasHyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesCalcium Metabolism DisordersBehavior, AnimalBehavior

Intervention Hierarchy (Ancestors)

Nutritional Physiological PhenomenaDiet, Food, and NutritionPhysiological Phenomena

Study Officials

  • Jean-Philippe Drouin-Chartier

    Laval University

    STUDY DIRECTOR
  • Jean-Philippe Drouin-Chartier

    Laval University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 6, 2021

First Posted

April 8, 2021

Study Start

July 1, 2021

Primary Completion

December 31, 2023

Study Completion

December 31, 2024

Last Updated

March 13, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations